🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

55 results for “intervention” Clear

  1. Premier Lifestyle Intervention with DASH Diet

    NORTHWEST BIOTHERAPEUTICS INC

    Weight Loss

    phase 2 other completed

    1 trial

  2. Standard intervention (counseling + self-help written materials)

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use

    phase 2 other completed

    1 trial

  3. Telehealth Intervention

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 2 other active

    1 trial

  4. WIDUS computer-delivered, indirect brief intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    phase 2 other completed

    1 trial

  5. telephone based skills training intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 other completed

    1 trial

  6. A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

    The George Institute

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    phase 1 other active

    1 trial

  7. A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

    The George Institute

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    phase 1 other active

    1 trial

  8. Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease

    H. Lundbeck A/S

    Active, moderate-to-severe TED

    phase 1 other active

    1 trial

  9. Motivational Network Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use

    phase 1 other completed

    1 trial

  10. No Intervention

    Takeda

    Rheumatoid Arthritis

    phase 1 other completed

    1 trial

  11. Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages

    BRIGHT MINDS BIOSCIENCES INC.

    Social Anxiety Disorder

    phase 1 other terminated

    1 trial

  12. Placebo pills for 14-day intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Controls

    phase 1 small molecule active

    1 trial

  13. Protexia

    United Therapeutics Europe Ltd

    Intervention for Nerve Agent Exposure

    phase 1 mab completed

    1 trial

  14. Therapeutic Workplace Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Addiction

    phase 1 other completed

    1 trial

  15. Woman-focused intervention

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 1 other completed

    1 trial

  16. Behavioral Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    approved other completed

    1 trial

  17. Berberine plus lifestyle intervention

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Obesity

    approved small molecule completed

    1 trial

  18. Oral hygiene intervention

    The University of Hong Kong

    Acute Stroke

    approved other completed

    1 trial

  19. XALKORI 200 mg hard capsules, XALKORI 250 mg hard capsules, Crizotinib 200 mg capsules, Crizotinib 250 mg capsules

    Pfizer Australia Pty Ltd

    This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed

    approved small molecule active

    1 trial

  20. AIM-CHD Mobile Health Intervention

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Secondary Prevention of Coronary Heart Disease

    other completed

    1 trial

  21. Dietary intervention + Physical Activity + Monitoring

    NORTHWEST BIOTHERAPEUTICS INC

    Gestational Diabetes

    other active

    1 trial

  22. Early Nutrition Intervention

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nutrition

    other completed

    1 trial

  23. High Fiber Diet Intervention

    Universal Integrated

    Dietary Fiber

    other completed

    1 trial

  24. Melatonin supplement intervention

    United Therapeutics Europe Ltd

    Physical Exercise

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources